$LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC.

2024 Q3 Form 10-Q Financial Statement

#000149315224030757 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $328.5K $370.0K
YoY Change -63.16% -70.22%
% of Gross Profit
Research & Development $361.6K $210.7K
YoY Change 172.96% -50.71%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $983.3K $1.009M
YoY Change -4.0% -39.57%
Operating Profit -$983.3K -$1.009M
YoY Change -4.0% -39.57%
Interest Expense $1.049K $4.154K
YoY Change 275.99% 113.24%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$986.0K -$1.011M
YoY Change -3.21% -39.41%
Income Tax
% Of Pretax Income
Net Earnings -$986.0K -$1.011M
YoY Change -3.21% -39.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.44 -$0.45
Diluted Earnings Per Share -$0.44 -$0.45
COMMON SHARES
Basic Shares Outstanding 2.249M shares 2.249M shares
Diluted Shares Outstanding 2.249M shares 2.249M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.638M $2.595M
YoY Change -67.92% -10.91%
Cash & Equivalents $1.638M $2.595M
Short-Term Investments
Other Short-Term Assets $51.34K $72.38K
YoY Change -60.23% -60.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.689M $2.668M
YoY Change -67.74% -13.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.930K
YoY Change
Total Long-Term Assets $6.928K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.689M $2.668M
Total Long-Term Assets $6.928K $0.00
Total Assets $1.696M $2.668M
YoY Change -67.6% -13.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $72.86K $131.4K
YoY Change -67.06% -64.15%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $329.0K $421.5K
YoY Change 5.52% 4.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $329.0K $421.5K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $329.0K $421.5K
YoY Change 5.52% 4.68%
SHAREHOLDERS EQUITY
Retained Earnings -$51.45M -$50.46M
YoY Change 8.43% 8.69%
Common Stock $225.00 $225.00
YoY Change 0.0% 35.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.367M $2.246M
YoY Change
Total Liabilities & Shareholders Equity $1.696M $2.668M
YoY Change -67.6% -13.81%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$986.0K -$1.011M
YoY Change -3.21% -39.41%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$957.6K -$819.0K
YoY Change 1.75% -30.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -957.6K -819.0K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -957.6K -819.0K
YoY Change -143.68% -30.32%
FREE CASH FLOW
Cash From Operating Activities -$957.6K -$819.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
17116 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4308620 usd
CY2024Q2 us-gaap Assets
Assets
2667604 usd
CY2023Q4 us-gaap Assets
Assets
4308620 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
131404 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
156758 usd
CY2024Q2 LIXT Research And Development Contract Liabilities Current
ResearchAndDevelopmentContractLiabilitiesCurrent
290061 usd
CY2023Q4 LIXT Research And Development Contract Liabilities Current
ResearchAndDevelopmentContractLiabilitiesCurrent
157100 usd
CY2024Q2 LIXT Advances On Research And Development Contract Services
AdvancesOnResearchAndDevelopmentContractServices
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
LIXT Share Based Compensation Included In Research And Development Cost
ShareBasedCompensationIncludedInResearchAndDevelopmentCost
usd
LIXT Share Based Compensation Included In Research And Development Cost
ShareBasedCompensationIncludedInResearchAndDevelopmentCost
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2023Q4 us-gaap Cash
Cash
4203488 usd
CY2023Q4 LIXT Advances On Research And Development Contract Services
AdvancesOnResearchAndDevelopmentContractServices
78016 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
10000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
421465 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
313858 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
3500000 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
3500000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2249290 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2249290 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
225 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
225 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49209883 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48976265 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50463969 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48481728 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2246139 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3994762 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2667604 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4308620 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
306354 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
522561 usd
CY2024Q2 LIXT Legal Fees Relating To Patents And Licensing
LegalFeesRelatingToPatentsAndLicensing
63612 usd
CY2023Q2 LIXT Legal Fees Relating To Patents And Licensing
LegalFeesRelatingToPatentsAndLicensing
340010 usd
CY2024Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
428482 usd
CY2023Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
379970 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
210708 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
427457 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1009156 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1669998 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1009156 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1669998 usd
CY2024Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2233 usd
CY2023Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2714 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
4154 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
1948 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
158 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
877 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1010919 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1668355 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.82
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2249290 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2249290 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1665956 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1665956 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2249290 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2249290 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1665479 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1665479 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3126367 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
130691 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1010919 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2246139 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3994762 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3994762 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
233618 usd
us-gaap Net Income Loss
NetIncomeLoss
-1982241 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2246139 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2246139 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4080829 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
280060 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1668355 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2692534 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5165227 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5165227 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6281 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
557040 usd
us-gaap Net Income Loss
NetIncomeLoss
-3036014 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2692534 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2692534 usd
us-gaap Net Income Loss
NetIncomeLoss
-1982241 usd
us-gaap Net Income Loss
NetIncomeLoss
-3036014 usd
LIXT Share Based Compensation Included In General And Administrative Cost
ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
233618 usd
LIXT Share Based Compensation Included In General And Administrative Cost
ShareBasedCompensationIncludedInGeneralAndAdministrativeCost
557040 usd
LIXT Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
-78016 usd
LIXT Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
-69002 usd
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
5442 usd
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
5426 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
39824 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
39183 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-25354 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
136764 usd
LIXT Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
132961 usd
LIXT Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
-128936 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1608266 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2446753 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6281 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6281 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1608266 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2440472 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4203488 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5353392 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2595222 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2912920 usd
us-gaap Interest Paid Net
InterestPaidNet
11340 usd
us-gaap Interest Paid Net
InterestPaidNet
5809 usd
CY2023Q2 LIXT Nasdaq Listing Maintaining Minimum Net Stockholders Equity
NasdaqListingMaintainingMinimumNetStockholdersEquity
2500000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2246139 usd
us-gaap Net Income Loss
NetIncomeLoss
-1982241 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1608266 usd
CY2024Q2 us-gaap Cash
Cash
2595222 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_z8k2c2pNE1T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 LIXT Cash Sipc Insured Amount
CashSIPCInsuredAmount
500000 usd
CY2024Q2 us-gaap Legal Fees
LegalFees
63612 usd
CY2023Q2 us-gaap Legal Fees
LegalFees
340010 usd
us-gaap Legal Fees
LegalFees
146823 usd
us-gaap Legal Fees
LegalFees
657350 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zfFlZodjMena" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company periodically contracts with vendors and consultants to provide services related to the Company’s operations. Charges incurred for these services can be for a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that represented <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zN5R96eHNle4"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKO0kodkb0E">10</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% or more of general and administrative costs or research and development costs for the three months ended June 30, 2024 and 2023 are described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative costs for the three months ended June 30, 2024 and 2023 include charges from legal firms and other vendors for general licensing and patent prosecution costs relating to the Company’s intellectual properties representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQtxUxUIeqq9" title="Concentration risk percentage">8.0</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2LPvxgOt1kg" title="Concentration risk percentage">27.3</span>% of total general and administrative costs, respectively. General and administrative costs for the three months ended June 30, 2024 and 2023 also included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zRrFM5Ur4b2" title="Concentration of risk, percentage">16.4</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zbIiCHXCaOBg" title="Concentration of risk, percentage">22.5</span>%, respectively, of total general and administrative costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs for the three months ended June 30, 2024 include charges from two vendors and consultants representing <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240401__20240630__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zTPJESLu4y8f" title="Concentration of risk, percentage">32.6</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240401__20240630__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zd3oyZNptrh6" title="Concentration of risk, percentage">37.9</span>%, respectively, of total research and development costs. Research and development costs for the three months ended June 30, 2023 include charges from two vendors and consultants representing <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zqiUfVcoa6pj" title="Concentration of risk, percentage">12.4</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zoRrcrBqtpq9" title="Concentration of risk, percentage">62.9</span>%, respectively, of total research and development costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and expenses incurred that represented <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z3FxYSr7rvq9" title="Concentration risk percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zxhp6NapqBE9" title="Concentration risk percentage">10</span></span>% or more of general and administrative costs or research and development costs for the six months ended June 30, 2024 and 2023 are described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative costs for the six months ended June 30, 2024 and 2023 include charges from legal firms and other vendors for general licensing and patent prosecution costs relating to the Company’s intellectual properties representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zq5RpWz7AbQk" title="Concentration risk percentage">8.9</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvrTKqNLwFI1" title="Concentration risk percentage">27.1</span>% of total general and administrative costs, respectively. General and administrative costs for the six months ended June 30, 2024 and 2023 also included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zEhItUMqUGX8" title="Concentration risk percentage">14.2</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zvR6ssNF1QLk" title="Concentration risk percentage">23.0</span>%, respectively, of total general and administrative costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs for the six months ended June 30, 2024 include charges from three vendors and consultants representing <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240630__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z60THkkEXWCf" title="Concentration of risk, percentage">11.0</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240630__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbxwhoeuuSp5" title="Concentration of risk, percentage">24.0</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240630__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zLmRDMbUUged" title="Concentration of risk, percentage">41.3</span>%, respectively, of total research and development costs. Research and development costs for the six months ended June 30, 2023 include charges from three vendors and consultants representing <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--MajorCustomersAxis__custom--VendorAndConsultantOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z2MaLgIRPPud" title="Concentration of risk, percentage">11.2</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--MajorCustomersAxis__custom--VendorAndConsultantTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zoXQ9DO0Tty9" title="Concentration of risk, percentage">17.1</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--MajorCustomersAxis__custom--VendorAndConsultantThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7zMv0n8U9jc" title="Concentration of risk, percentage">43.6</span>%, respectively, of total research and development costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1486630 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
691177 shares
CY2024Q2 LIXT Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.0780 pure
CY2023Q2 LIXT Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.0899 pure
LIXT Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.0814 pure
LIXT Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.0816 pure
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
210708 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
427457 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
329772 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
616542 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
210708 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
427457 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
329772 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
616542 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2249290 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2249290 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2249290 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2249290 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
808365 shares
CY2021Q2 us-gaap Cash
Cash
40000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.125 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.04290 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2645 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.04565 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3805 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y6M
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
130691 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
280060 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
233618 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
557040 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
552083 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.330
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
56598 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.370
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3333 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
66.000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
605348 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.840
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M3D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
252292 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
28.387
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
327849 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
21.961
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y10M6D
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
538000 usd
CY2024Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
605348 shares
CY2024Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
327849 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.37
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
26000 usd
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
277500 shares
CY2024Q2 us-gaap Other Commitment
OtherCommitment
3467000 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-030757-index-headers.html Edgar Link pending
0001493152-24-030757-index.html Edgar Link pending
0001493152-24-030757.txt Edgar Link pending
0001493152-24-030757-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
lixt-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lixt-20240630_cal.xml Edgar Link unprocessable
lixt-20240630_def.xml Edgar Link unprocessable
lixt-20240630_lab.xml Edgar Link unprocessable
lixt-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending